CHCHD4P2

Across TCGA pan-cancer cohorts, CHCHD4P2 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated CHCHD4P2 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CHCHD4P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHCHD4P2 expression acts as an unfavorable survival marker, although some lineages such as CHOL and STAD show a favorable association.

LUAD, TGCT, and KIRC are the cancer types where CHCHD4P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.122	0.356	.005	84	view →
TGCT	OS	Tertile	III,IV	0.003	1.000	<.001	72	view →
KIRC	OS	Quartile	All	0.530	0.671	<.001	60	view →
ACC	DFS	Tertile	All	0.111	0.559	.002	57	view →
LIHC	DFS	Tertile	All	0.178	0.543	<.001	57	view →
UCS	DFS	Tertile	IV	0.192	0.776	<.001	36	view →
LAML	DFS	Quartile	All	0.396	0.651	.001	30	view →
BLCA	OS	Tertile	IV	0.193	0.480	.007	27	view →
CHOL	DFS	Tertile	All	0.819	0.282	.018	27	view →
READ	DFS	Tertile	All	0.141	0.583	.035	18	view →
STAD	DFS	Median	All	0.446	0.301	.015	16	view →
ESCA	DFS	Tertile	IV	0.692	0.216	.024	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 17 lineages.

CHCHD4P2–LUAD (DFS)

Open the LUAD breakdown →